attenuated arsenic trioxide (ATO) plus low-dose all-trans retinoic acid (ATRA)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for attenuated arsenic trioxide (ATO) plus low-dose all-trans retinoic acid (ATRA), covering 2022-10-26 to 2022-10-26. Get the full timeline:
Most recent: Clinical Trial Update: Effectiveness and Safety of Therapy Based on Attenuated ATO Plus Low-Dose ATRA in Patients With APL [Phase 1, Phase 2]